Product Description
LTX-109 isa novel antimicrobial agent with a membrane lysing mode of action.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lytix Biopharma AS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Norway, Sweden
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Healthy Volunteers|Hidradenitis Suppurativa|Staphylococcal Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| C22-109-08 | P2 |
Completed |
Staphylococcal Infections |
2022-10-28 |
24% |
| 2022-001938-11 | P2 |
Completed |
Healthy Volunteers |
2022-10-24 |
|
| C20-109-07 | P2 |
Completed |
Hidradenitis Suppurativa |
2021-07-01 |
50% |
| C20-109-06 | P2 |
Completed |
Staphylococcal Infections |
2021-03-23 |
31% |